Paper Details

  1. Home
  2. Paper Details

Differential CD4+ cell count increase and CD4+ :  CD8+ ratio normalization with maraviroc compared with tenofovir.

Author: BrownTodd T, ChanEllen S, EronJoseph J, FichtenbaumCarl J, KlingmanKarin L, LandayAlan L, MartinsonJeffrey, MirmonsefParia, OfotokunIgho, PlantsJill, RibaudoHeather J, TaiwoBabafemi O, WeitzmannM Neale

Clinical Trial, Phase IIA Phase II trial is a trial that further evaluates the efficacy and safety of a new drug or treatment, whose safety has been confirmed to some extent in a Phase I trial, in a small number of patients.
Comparative StudyResearch that compares multiple groups/interventions to determine differences/similarities in outcomes/characteristics.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This study aimed to determine whether maraviroc (MVC) has differential immunologic effects compared with tenofovir disoproxil fumarate (TDF) during initial antiretroviral therapy.
Paper Details　
Original Abstract of the Article :
Studies exploring the immunologic effects of maraviroc (MVC) have produced mixed results; hence, it remains unclear whether MVC has unique immunologic effects in comparison with other antiretroviral drugs. We sought to determine whether MVC has differential effects compared with tenofovir disoproxil...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/27281061

データ提供：米国国立医学図書館（NLM）

Maraviroc vs. Tenofovir: A Comparative Study of Immunologic Effects in HIV Treatment

The fight against [HIV] is a relentless journey, demanding innovative therapies and a deep understanding of the virus's behavior. This research focuses on the immunologic effects of two antiretroviral drugs, maraviroc (MVC) and tenofovir disoproxil fumarate (TDF). The authors used a rigorous [clinical trial design] to compare the effects of these drugs on CD4+ cell count, a key indicator of immune system health. Their findings reveal that MVC leads to a more pronounced increase in CD4+ cell count and normalization of the CD4+:CD8+ ratio compared to TDF. This discovery adds a vital piece to the puzzle of HIV treatment, highlighting the potential of MVC to improve immune function in patients.

MVC: A Beacon of Hope for Immune Restoration in HIV Patients

These findings offer a glimmer of hope for patients with HIV. The discovery that MVC may enhance immune function is like finding a hidden spring in the arid landscape of the immune system. This could translate to improved quality of life and potentially a greater chance of achieving long-term viral suppression.

The Quest for Personalized HIV Treatment: A Collaborative Effort

This research underscores the importance of [personalized medicine] in HIV treatment. Understanding the individual responses to different medications is crucial for optimizing treatment outcomes. It's like navigating a vast desert, where each path requires a unique strategy to reach the destination. This research highlights the ongoing quest for personalized HIV therapies, which will require continued collaboration between scientists, clinicians, and patients.

Dr.Camel's Conclusion

This study offers a compelling case for the importance of personalized HIV treatment strategies. It's akin to a camel caravan adjusting its route based on the shifting sands of individual patient needs. By focusing on the unique immunologic effects of different drugs, we can pave the way for more effective and individualized approaches to HIV management.

Date :
  1. Date Completed 2017-12-18
  2. Date Revised 2018-12-02
Further Info :

Pubmed ID

27281061

DOI: Digital Object Identifier

NIHMS800564

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.